Interchange Capital Partners LLC Lowers Stake in CRISPR Therapeutics AG $CRSP

Interchange Capital Partners LLC cut its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 9.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,720 shares of the company’s stock after selling 699 shares during the quarter. Interchange Capital Partners LLC’s holdings in CRISPR Therapeutics were worth $327,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of CRSP. Janney Montgomery Scott LLC grew its holdings in shares of CRISPR Therapeutics by 55.7% during the first quarter. Janney Montgomery Scott LLC now owns 10,703 shares of the company’s stock worth $364,000 after buying an additional 3,827 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in CRISPR Therapeutics by 14.3% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company’s stock valued at $1,334,000 after purchasing an additional 4,914 shares during the period. Westside Investment Management Inc. grew its holdings in CRISPR Therapeutics by 29.1% in the first quarter. Westside Investment Management Inc. now owns 7,942 shares of the company’s stock valued at $269,000 after purchasing an additional 1,790 shares during the period. GF Fund Management CO. LTD. grew its holdings in CRISPR Therapeutics by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company’s stock valued at $74,000 after purchasing an additional 394 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in CRISPR Therapeutics by 1.5% in the first quarter. Bank of New York Mellon Corp now owns 77,702 shares of the company’s stock valued at $2,644,000 after purchasing an additional 1,133 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 50,895 shares of the business’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the transaction, the chief executive officer directly owned 254,201 shares of the company’s stock, valued at approximately $17,262,789.91. The trade was a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 1,076 shares of the business’s stock in a transaction on Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the transaction, the general counsel directly owned 83,402 shares in the company, valued at approximately $5,554,573.20. The trade was a 1.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,213 shares of company stock worth $3,810,458. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Stock Up 0.6%

Shares of CRSP stock opened at $67.61 on Monday. The stock has a market cap of $6.15 billion, a price-to-earnings ratio of -12.45 and a beta of 1.84. CRISPR Therapeutics AG has a fifty-two week low of $30.04 and a fifty-two week high of $78.48. The firm’s 50 day moving average price is $61.62 and its two-hundred day moving average price is $51.52.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.18. The firm had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. CRISPR Therapeutics’s revenue was up 72.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.49) earnings per share. On average, equities analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Analyst Ratings Changes

CRSP has been the subject of a number of recent analyst reports. Chardan Capital restated a “buy” rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Needham & Company LLC restated a “buy” rating and issued a $81.00 target price on shares of CRISPR Therapeutics in a report on Friday, October 10th. Wells Fargo & Company set a $75.00 target price on shares of CRISPR Therapeutics in a report on Monday, October 13th. Royal Bank Of Canada boosted their target price on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the company a “sector perform” rating in a report on Tuesday, August 5th. Finally, Zacks Research raised shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Ten analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $72.59.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.